Connect Biopharma Holdings Limited (CNTB)
Develops an antibody drug to treat severe asthma and COPD flare-ups
$2.08-0.01%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago+4.0%
The outlook
CNTB is trading near its 52-week lows with analysts overwhelmingly rating it a Strong Buy and setting an average price target around 243% above the current level. The stock sits below both its 50- and 200-day moving averages, suggesting a weak near-term trend despite the bullish analyst sentiment.
What’s behind the score
Analyst consensusStrong Buy — 1.1 avg of 8 analysts
Price trendBelow its 50- & 200-day averages
52-week range33% of the way from its 52-week low to high
Price targetAvg target +243% vs current price
Analyst price target
~12-month · 8 analysts$7.13average target+242.5% vs now
Now $2.08
Low $4.00High $10.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$131.0M
52-wk high
$3.82
52-wk low
$1.23
50-day avg
$2.25
200-day avg
$2.40
Trailing P/E
—